Dominique Custeau

The pro-apoptotic protein, Bik, exhibits potent antitumor activity that is dependent on its BH3 domain.

T. Chittenden, H. Gourdeau, C. Vater, 2001, Molecular cancer therapeutics.

Identification of amidoheteroaryls as potent inhibitors of mutant (V600E) B-Raf kinase with in vivo activity.

David A. Scott, P. Lyne, L. Drew, 2009, Bioorganic & medicinal chemistry letters.

Antivascular and antitumor evaluation of 2-amino-4-(3-bromo-4,5-dimethoxy-phenyl)-3-cyano-4H-chromenes, a novel series of anticancer agents.

H. Gourdeau, S. Kasibhatla, L. Geerts, 2004, Molecular cancer therapeutics.

Species Differences in Troxacitabine Pharmacokinetics and Pharmacodynamics

H. Gourdeau, J. Jolivet, L. Leblond, 2004, Clinical Cancer Research.